CytoDyn Inc. SEC filings CYDY
CytoDyn Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 15, 2015. Its latest annual report, Form 10-K, was filed on Aug 31, 2026 for the period ended May 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 14, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on May 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 20, 2026 | Oct 20, 2026 |
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Oct 14, 2026 | Aug 31, 2026 |
| EFFECT | Filing | Oct 7, 2026 | — |
| 424B3 | Prospectus | Oct 7, 2026 | — |
| EFFECT | Filing | Oct 2, 2026 | — |
| EFFECT | Filing | Oct 2, 2026 | — |
| DEF 14A | Proxy statement | Sep 28, 2026 | Sep 28, 2026 |
| S-3 | Shelf registration | Sep 25, 2026 | — |
| POS AM | Filing | Sep 25, 2026 | — |
| POS AM | Filing | Sep 25, 2026 | — |
| 10-K | Annual report | Aug 31, 2026 | May 31, 2026 |
| EFFECT | Filing | May 20, 2026 | — |
| 424B3 | Prospectus | May 20, 2026 | — |
| D | Filing | May 11, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 30, 2026 | Apr 30, 2026 |
| S-1 | Registration statement | Apr 22, 2026 | — |
| 424B3 | Prospectus | Apr 8, 2026 | — |
| 10-Q | Quarterly report | Apr 8, 2026 | Feb 28, 2026 |
| 424B3 | Prospectus | Mar 25, 2026 | — |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 24, 2026 | Mar 24, 2026 |
| 424B3 | Prospectus | Mar 9, 2026 | — |
| 8-K |
Current report
Unregistered share sale
|
Mar 5, 2026 | Feb 27, 2026 |
| 424B3 | Prospectus | Jan 9, 2026 | — |
| 10-Q | Quarterly report | Jan 9, 2026 | Nov 30, 2025 |
| 424B3 | Prospectus | Dec 22, 2025 | — |
| EFFECT | Filing | Dec 16, 2025 | — |
| POS AM | Filing | Dec 10, 2025 | — |
| EFFECT | Filing | Dec 2, 2025 | — |
| 424B3 | Prospectus | Dec 2, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 1, 2025 | Nov 23, 2025 |
| CORRESP | Letter to the SEC | Nov 26, 2025 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Nov 21, 2025 | Nov 21, 2025 |
| S-3 | Shelf registration | Nov 4, 2025 | — |
| DEFA14A | Additional proxy material | Nov 3, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 3, 2025 | Nov 3, 2025 |
| 10-Q | Quarterly report | Oct 10, 2025 | Aug 31, 2025 |
| DEFA14A | Additional proxy material | Sep 30, 2025 | — |
| 424B3 | Prospectus | Sep 29, 2025 | — |
| DEF 14A | Proxy statement | Sep 29, 2025 | Nov 21, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 19, 2025 | Nov 21, 2025 |
| EFFECT | Filing | Aug 21, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| CORRESP | Letter to the SEC | Aug 18, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2025 | — |
| S-3 | Shelf registration | Jul 25, 2025 | — |
| 10-K | Annual report | Jul 25, 2025 | May 31, 2025 |
| 4 | Insider transaction | May 22, 2025 | May 15, 2025 |
| 3 | Initial insider ownership | May 22, 2025 | May 15, 2025 |
| 424B3 | Prospectus | May 16, 2025 | — |
| 8-K |
Current report
Auditor change
|
May 16, 2025 | May 14, 2025 |
| 424B3 | Prospectus | May 6, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 6, 2025 | May 2, 2025 |
| 424B3 | Prospectus | Apr 15, 2025 | — |
| 10-Q | Quarterly report | Apr 14, 2025 | Feb 28, 2025 |
| 424B3 | Prospectus | Jan 14, 2025 | — |
| 10-Q | Quarterly report | Jan 14, 2025 | Nov 30, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Nov 22, 2024 | Nov 22, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 4 | Insider transaction | Oct 30, 2024 | Oct 28, 2024 |
| 424B3 | Prospectus | Oct 17, 2024 | — |
| 10-Q | Quarterly report | Oct 15, 2024 | Aug 31, 2024 |
| DEF 14A | Proxy statement | Oct 11, 2024 | Nov 22, 2024 |
| EFFECT | Filing | Oct 1, 2024 | — |
| 424B3 | Prospectus | Oct 1, 2024 | — |
| 10-K/A | Amended annual report | Sep 30, 2024 | May 31, 2024 |
| CORRESP | Letter to the SEC | Sep 26, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2024 | — |
| EFFECT | Filing | Sep 12, 2024 | — |
| EFFECT | Filing | Sep 12, 2024 | — |
| POS AM | Filing | Sep 9, 2024 | — |
| POS AM | Filing | Sep 9, 2024 | — |
| S-1 | Registration statement | Sep 9, 2024 | — |
| 10-K | Annual report | Aug 15, 2024 | May 31, 2024 |
| SC TO-I/A | Filing | Jul 22, 2024 | — |
| 424B3 | Prospectus | Jul 9, 2024 | — |
| 424B3 | Prospectus | Jul 9, 2024 | — |
| SC TO-I/A | Filing | Jul 9, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 9, 2024 | Jul 2, 2024 |
| CORRESP | Letter to the SEC | Jun 28, 2024 | — |
| SC TO-I/A | Filing | Jun 28, 2024 | — |
| 8-K |
Current report
Auditor change
|
Jun 28, 2024 | Jun 28, 2024 |
| CORRESP | Letter to the SEC | Jun 20, 2024 | — |
| SC TO-I/A | Filing | Jun 20, 2024 | — |
| CORRESP | Letter to the SEC | Jun 12, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2024 | — |
| 8-K |
Current report
Unregistered share sale
|
Jun 3, 2024 | May 28, 2024 |
| SC TO-I | Filing | Jun 3, 2024 | — |
| 424B3 | Prospectus | May 6, 2024 | — |
| 424B3 | Prospectus | May 6, 2024 | — |
| 8-K |
Current report
Auditor change
|
May 6, 2024 | May 6, 2024 |
| 424B3 | Prospectus | Apr 16, 2024 | — |
| 424B3 | Prospectus | Apr 16, 2024 | — |
| 10-Q | Quarterly report | Apr 15, 2024 | Feb 29, 2024 |
| 424B3 | Prospectus | Apr 8, 2024 | — |
| 424B3 | Prospectus | Apr 8, 2024 | — |
| 8-K |
Current report
Agreement ended
|
Apr 8, 2024 | Apr 3, 2024 |
| 8-K |
Current report
Unregistered share sale
|
Mar 28, 2024 | Mar 22, 2024 |
| 4 | Insider transaction | Mar 8, 2024 | Mar 7, 2024 |
| 424B3 | Prospectus | Mar 1, 2024 | — |
| 424B3 | Prospectus | Mar 1, 2024 | — |
| 424B3 | Prospectus | Feb 22, 2024 | — |
| EFFECT | Filing | Feb 21, 2024 | — |
| 3 | Initial insider ownership | Feb 15, 2024 | Feb 1, 2024 |
| CORRESP | Letter to the SEC | Feb 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| S-1 | Registration statement | Feb 7, 2024 | — |
| 424B3 | Prospectus | Jan 29, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 29, 2024 | Jan 23, 2024 |
| 424B3 | Prospectus | Jan 19, 2024 | — |
| 10-Q | Quarterly report | Jan 16, 2024 | Nov 30, 2023 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 8-K |
Current report
Other events
|
Dec 22, 2023 | Dec 19, 2023 |
| 424B3 | Prospectus | Dec 15, 2023 | — |
| 8-K |
Current report
Other events
|
Dec 14, 2023 | Dec 14, 2023 |
| 3 | Initial insider ownership | Nov 29, 2023 | Nov 17, 2023 |
| 424B3 | Prospectus | Nov 28, 2023 | — |
| 8-K |
Current report
Agreement ended
|
Nov 28, 2023 | Nov 21, 2023 |
| 424B3 | Prospectus | Nov 22, 2023 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 21, 2023 | Nov 17, 2023 |
| 424B3 | Prospectus | Nov 13, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 6, 2023 | Nov 3, 2023 |
| DEFA14A | Additional proxy material | Nov 6, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Oct 25, 2023 | — |
| 424B3 | Prospectus | Oct 24, 2023 | — |
| 10-Q | Quarterly report | Oct 23, 2023 | Aug 31, 2023 |
| NT 10-Q | Filing | Oct 16, 2023 | Aug 31, 2023 |
| 424B3 | Prospectus | Oct 11, 2023 | — |
| DEFA14A | Additional proxy material | Oct 10, 2023 | — |
| 8-K |
Current report
Auditor change
|
Oct 10, 2023 | Oct 6, 2023 |
| EFFECT | Filing | Oct 5, 2023 | — |
| POS AM | Filing | Oct 2, 2023 | — |
| DEFA14A | Additional proxy material | Sep 27, 2023 | — |
| DEF 14A | Proxy statement | Sep 25, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Auditor change
|
Sep 25, 2023 | Sep 19, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 15, 2023 | Nov 9, 2023 |
| 10-K | Annual report | Sep 14, 2023 | May 31, 2023 |
| NT 10-K | Filing | Aug 30, 2023 | May 31, 2023 |
| 3 | Initial insider ownership | Aug 25, 2023 | Aug 15, 2023 |
| 8-K |
Current report
Unregistered share sale
|
Aug 17, 2023 | Aug 11, 2023 |
| 424B3 | Prospectus | Jul 11, 2023 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 11, 2023 | Jul 6, 2023 |
| EFFECT | Filing | Jul 10, 2023 | — |
| CORRESP | Letter to the SEC | Jul 6, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2023 | — |
| S-1 | Registration statement | Jun 21, 2023 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 24, 2023 | May 18, 2023 |
| 10-Q | Quarterly report | Apr 10, 2023 | Feb 28, 2023 |
| 8-K |
Current report
Unregistered share sale
|
Mar 8, 2023 | Mar 2, 2023 |
| 8-K |
Current report
Unregistered share sale
|
Mar 2, 2023 | Feb 24, 2023 |
| 4 | Insider transaction | Feb 14, 2023 | Feb 13, 2023 |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| POS AM | Filing | Feb 3, 2023 | — |
| 8-K |
Current report
Unregistered share sale
|
Feb 1, 2023 | Jan 26, 2023 |
| 10-Q | Quarterly report | Jan 9, 2023 | Nov 30, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 19, 2022 | Dec 19, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Dec 9, 2022 | Dec 9, 2022 |
| DEFA14A | Additional proxy material | Dec 7, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 7, 2022 | Dec 7, 2022 |
| DEFA14A | Additional proxy material | Dec 7, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 7, 2022 | Nov 30, 2022 |
| 4 | Insider transaction | Nov 30, 2022 | Nov 28, 2022 |
| 4 | Insider transaction | Nov 30, 2022 | Nov 28, 2022 |
| DEFA14A | Additional proxy material | Nov 25, 2022 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CYDY (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Vancouver, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1175680
- Former names
- CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.